February 2011
As more specialty pharmaceuticals products continue to come to the market, the manufacturer's goal should be to understand what will impact payer coverage.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Enfortumab Vedotin Plus Pembrolizumab Shows Promise as a Platinum-Free Option in Earlier Bladder Cancer
2
FDA Approves Rucaparib for the Treatment of Adults With mCRPC
3
Updates in Treatment of Unresectable Hepatocellular Carcinoma
4
Notable Updates in Medication Therapy Management in 2025
5